,8 For patients with EGFR-mutated NSCLC, a post hoc analysis of the RELAY (Ramucirumab Plus Erlotinib Versus Placebo) trial indicated that the addition of ramucirumab (a vascular endothelial growth factor receptor 2 inhibitor) to erlotinib (a first-generation EGFR tyrosine kinase inhibitor) improves treatment outcome in patients with a concurrent TP53 mutation.9 Here, EGFR is linked to non-small cell lung carcinoma.